159 related articles for article (PubMed ID: 17233818)
1. Beta1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells.
Hazlehurst LA; Argilagos RF; Dalton WS
Br J Haematol; 2007 Jan; 136(2):269-75. PubMed ID: 17233818
[TBL] [Abstract][Full Text] [Related]
2. H2AX phosphorylation regulated by p38 is involved in Bim expression and apoptosis in chronic myelogenous leukemia cells induced by imatinib.
Dong Y; Xiong M; Duan L; Liu Z; Niu T; Luo Y; Wu X; Xu C; Lu C
Apoptosis; 2014 Aug; 19(8):1281-92. PubMed ID: 24830786
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia.
San José-Eneriz E; Agirre X; Jiménez-Velasco A; Cordeu L; Martín V; Arqueros V; Gárate L; Fresquet V; Cervantes F; Martínez-Climent JA; Heiniger A; Torres A; Prósper F; Roman-Gomez J
Eur J Cancer; 2009 Jul; 45(10):1877-89. PubMed ID: 19403302
[TBL] [Abstract][Full Text] [Related]
4. Bim protein degradation contributes to cisplatin resistance.
Wang J; Zhou JY; Wu GS
J Biol Chem; 2011 Jun; 286(25):22384-92. PubMed ID: 21561860
[TBL] [Abstract][Full Text] [Related]
5. The roles of epigenetic modifications of proapoptotic BID and BIM genes in imatinib-resistant chronic myeloid leukemia cells.
Bozkurt S; Özkan T; Özmen F; Baran Y; Sunguroğlu A; Kansu E
Hematology; 2013 Jul; 18(4):217-23. PubMed ID: 23394612
[TBL] [Abstract][Full Text] [Related]
6. Apoptosis and autophagy have opposite roles on imatinib-induced K562 leukemia cell senescence.
Drullion C; Trégoat C; Lagarde V; Tan S; Gioia R; Priault M; Djavaheri-Mergny M; Brisson A; Auberger P; Mahon FX; Pasquet JM
Cell Death Dis; 2012 Aug; 3(8):e373. PubMed ID: 22898871
[TBL] [Abstract][Full Text] [Related]
7. Thiazolides promote apoptosis in colorectal tumor cells via MAP kinase-induced Bim and Puma activation.
Brockmann A; Bluwstein A; Kögel A; May S; Marx A; Tschan MP; Brunner T
Cell Death Dis; 2015 Jun; 6(6):e1778. PubMed ID: 26043078
[TBL] [Abstract][Full Text] [Related]
8. FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors.
Kiyota M; Kuroda J; Yamamoto-Sugitani M; Shimura Y; Nakayama R; Nagoshi H; Mizutani S; Chinen Y; Sasaki N; Sakamoto N; Kobayashi T; Matsumoto Y; Horiike S; Taniwaki M
Apoptosis; 2013 Nov; 18(11):1437-1446. PubMed ID: 23851982
[TBL] [Abstract][Full Text] [Related]
9. EGFR-dependent downregulation of Bim in epithelial cells requires MAPK and PKC-delta activities.
Quadros MR; Connelly S; Kari C; Abrams MT; Wickstrom E; Rodeck U
Cancer Biol Ther; 2006 May; 5(5):498-504. PubMed ID: 16582597
[TBL] [Abstract][Full Text] [Related]
10. MEK inhibitors potentiate dexamethasone lethality in acute lymphoblastic leukemia cells through the pro-apoptotic molecule BIM.
Rambal AA; Panaguiton ZL; Kramer L; Grant S; Harada H
Leukemia; 2009 Oct; 23(10):1744-54. PubMed ID: 19404317
[TBL] [Abstract][Full Text] [Related]
11. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
[TBL] [Abstract][Full Text] [Related]
12. Thiazolide-induced apoptosis in colorectal cancer cells is mediated via the Jun kinase-Bim axis and reveals glutathione-S-transferase P1 as Achilles' heel.
Sidler D; Brockmann A; Mueller J; Nachbur U; Corazza N; Renzulli P; Hemphill A; Brunner T
Oncogene; 2012 Sep; 31(37):4095-106. PubMed ID: 22158036
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells.
Shen Y; Ren X; Ding K; Zhang Z; Wang D; Pan J
Oncotarget; 2014 Nov; 5(21):10407-20. PubMed ID: 25431951
[TBL] [Abstract][Full Text] [Related]
14. Glucocorticoid-mediated BIM induction and apoptosis are regulated by Runx2 and c-Jun in leukemia cells.
Heidari N; Miller AV; Hicks MA; Marking CB; Harada H
Cell Death Dis; 2012 Jul; 3(7):e349. PubMed ID: 22825467
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic kit triggers Shp2/Erk1/2 pathway to down-regulate the pro-apoptotic protein Bim and to promote apoptosis resistance in leukemic cells.
Selimoglu-Buet D; Gallais I; Denis N; Guillouf C; Moreau-Gachelin F
PLoS One; 2012; 7(11):e49052. PubMed ID: 23145067
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function.
Luciano F; Jacquel A; Colosetti P; Herrant M; Cagnol S; Pages G; Auberger P
Oncogene; 2003 Oct; 22(43):6785-93. PubMed ID: 14555991
[TBL] [Abstract][Full Text] [Related]
17. Erythropoietin-induced phosphorylation/degradation of BIM contributes to survival of erythroid cells.
Abutin RM; Chen J; Lung TK; Lloyd JA; Sawyer ST; Harada H
Exp Hematol; 2009 Feb; 37(2):151-8. PubMed ID: 19100675
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
[TBL] [Abstract][Full Text] [Related]
19. Regulation of the proapoptotic BH3-only protein BIM by glucocorticoids, survival signals and proteasome in chronic lymphocytic leukemia cells.
Iglesias-Serret D; de Frias M; Santidrián AF; Coll-Mulet L; Cosialls AM; Barragán M; Domingo A; Gil J; Pons G
Leukemia; 2007 Feb; 21(2):281-7. PubMed ID: 17151701
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
